Elisabeth Bendstrup

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4425341/publications.pdf

Version: 2024-02-01

152 papers	4,463 citations	147801 31 h-index	123424 61 g-index
160 all docs	160 docs citations	160 times ranked	4299 citing authors

#	Article	IF	Citations
1	Diagnosis of Hypersensitivity Pneumonitis in Adults: An Official ATS/JRS/ALAT Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2020, 202, e36-e69.	5.6	508
2	Multicentre evaluation of multidisciplinary team meeting agreement on diagnosis in diffuse parenchymal lung disease: a case-cohort study. Lancet Respiratory Medicine,the, 2016, 4, 557-565.	10.7	337
3	A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality. Annals of the Rheumatic Diseases, 2017, 76, 1700-1706.	0.9	263
4	Palliative care in interstitial lung disease: living well. Lancet Respiratory Medicine,the, 2017, 5, 968-980.	10.7	185
5	Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1656-1665.	5.6	171
6	Global incidence and prevalence of idiopathic pulmonary fibrosis. Respiratory Research, 2021, 22, 197.	3.6	170
7	Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management. Current Medical Research and Opinion, 2019, 35, 2015-2024.	1.9	148
8	A cohort study of interstitial lung diseases in central Denmark. Respiratory Medicine, 2014, 108, 793-799.	2.9	128
9	How does comorbidity influence survival in idiopathic pulmonary fibrosis?. Respiratory Medicine, 2014, 108, 647-653.	2.9	125
10	Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respiratory Medicine,the, 2016, 4, 445-453.	10.7	108
11	Managing the supportive care needs of those affected by COVID-19. European Respiratory Journal, 2020, 55, 2000815.	6.7	95
12	Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 199-208.	5.6	90
13	Updated guidance on the management of COVID-19: from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020). European Respiratory Review, 2020, 29, 200287.	7.1	82
14	Risk factors for diagnostic delay in idiopathic pulmonary fibrosis. Respiratory Research, 2019, 20, 103.	3.6	78
15	Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international caseâ€“cohort study. European Respiratory Journal, 2017, 50, 1700936.	6.7	75
16	Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation. European Respiratory Journal, 2020, 55, 1901760.	6.7	61
17	Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1146-1153.	5.6	60
18	Autoimmune pulmonary alveolar proteinosis: Treatment options in year 2013. Respirology, 2013, 18, 82-91.	2.3	58

#	Article	IF	Citations
19	Unclassifiable interstitial lung diseases: Clinical characteristics and survival. Respirology, 2017, 22, 494-500.	2.3	58
20	Idiopathic Pulmonary Fibrosis: Best Practice in Monitoring and Managing a Relentless Fibrotic Disease. Respiration, 2020, 99, 73-82.	2.6	58
21	Preferred Place of Care and Death in Terminally Ill Patients with Lung and Heart Disease Compared to Cancer Patients. Journal of Palliative Medicine, 2017, 20, 1217-1224.	1.1	54
22	Mindfulness-based cognitive therapy in COPD: a cluster randomised controlledÂtrial. European Respiratory Journal, 2018, 51, 1702082.	6.7	52
23	Interstitial Lung Disease in Rheumatoid Arthritis Remains a Challenge for Clinicians. Journal of Clinical Medicine, 2019, 8, 2038.	2.4	51
24	Opioids: an unexplored option for treatment of dyspnea in IPF. European Clinical Respiratory Journal, 2016, 3, 30629.	1.5	48
25	Rheumatoid Arthritis-Associated Interstitial Lung Disease: Clinical Characteristics and Predictors of Mortality. Respiration, 2019, 98, 455-460.	2.6	47
26	Pulmonary alveolar microlithiasis: two case reports and review of the literature. European Respiratory Review, 2012, 21, 249-256.	7.1	45
27	Introduction of cryobiopsies in the diagnostics of interstitial lung diseases â€“ experiences in a referral center. European Clinical Respiratory Journal, 2017, 4, 1274099.	1.5	44
28	Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary Fibrosis. Respiration, 2018, 95, 317-326.	2.6	42
29	Nintedanib in Idiopathic Pulmonary Fibrosis: Practical Management Recommendations for Potential Adverse Events. Respiration, 2019, 97, 173-184.	2.6	39
30	Validation of the IPF-specific version of St. Georgeâ€™s Respiratory Questionnaire. Respiratory Research, 2019, 20, 199.	3.6	37
31	A systematic review of occupational exposure to coal dust and the risk of interstitial lung diseases. European Clinical Respiratory Journal, 2017, 4, 1264711.	1.5	35
32	The need for a holistic approach for SSc-ILD â€“ achievements and ambiguity in a devastating disease. Respiratory Research, 2020, 21, 197.	3.6	33
33	Desquamative interstitial pneumonia: a systematic review of its features and outcomes. European Respiratory Review, 2020, 29, 190181.	7.1	32
34	Acute exacerbation of interstitial lung disease associated with rheumatic disease. Nature Reviews Rheumatology, 2022, 18, 85-96.	8.0	28
35	Treatment of idiopathic pulmonary fibrosis: a position paper from a Nordic expert group. Journal of Internal Medicine, 2017, 281, 149-166.	6.0	27
36	Tele-Rehabilitation Program in Idiopathic Pulmonary Fibrosisâ€”A Single-Center Randomized Trial. International Journal of Environmental Research and Public Health, 2021, 18, 10016.	2.6	27

#	Article	IF	Citations
37	Pulmonary manifestations of pyoderma gangrenosum: 2 cases and a review of the literature. Respiratory Medicine, 2015, 109, 443-450.	2.9	26
38	Pirfenidone treatment in idiopathic pulmonary fibrosis: nationwide Danish results. European Clinical Respiratory Journal, 2016, 3, 32608.	1.5	26
39	Birtâ€“Hoggâ€“DubÃ© syndrome: a case report and a review of the literature. European Clinical Respiratory Journal, 2017, 4, 1292378.	1.5	24
40	Increased mortality among patients with rheumatoid arthritis and COPD: A population-based study. Respiratory Medicine, 2018, 140, 101-107.	2.9	22
41	Validation of the Kingâ€™s Brief Interstitial Lung Disease questionnaire in Idiopathic Pulmonary Fibrosis. BMC Pulmonary Medicine, 2019, 19, 255.	2.0	22
42	Palliation of chronic breathlessness with morphine in patients with fibrotic interstitial lung disease â€“ a randomised placebo-controlled trial. Respiratory Research, 2020, 21, 195.	3.6	22
43	The DIAMORFOSIS (DIAgnosis and Management Of lung canceR and FibrOSIS) survey: international survey and call for consensus. ERJ Open Research, 2021, 7, 00529-2020.	2.6	22
44	Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities. Respiratory Research, 2021, 22, 125.	3.6	22
45	SLC34A2 Gene Mutation May Explain Comorbidity of Pulmonary Alveolar Microlithiasis and Aortic Valve Sclerosis. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 464-464.	5.6	21
46	Rituximab-induced interstitial lung disease: five case reports. European Clinical Respiratory Journal, 2015, 2, 27178.	1.5	21
47	Responsiveness and minimal clinically important difference of SGRQ-I and K-BILD in idiopathic pulmonary fibrosis. Respiratory Research, 2020, 21, 91.	3.6	21
48	Risk of hypersensitivity pneumonitis and interstitial lung diseases among pigeon breeders. European Respiratory Journal, 2016, 48, 818-825.	6.7	20
49	Turnover of type I and III collagen predicts progression of idiopathic pulmonary fibrosis. Respiratory Research, 2021, 22, 205.	3.6	20
50	Voriconazole Concentrations in Plasma and Epithelial Lining Fluid after Inhalation and Oral Treatment. Basic and Clinical Pharmacology and Toxicology, 2017, 121, 430-434.	2.5	19
51	Screening tools for evaluation of depression in Chronic Obstructive Pulmonary Disease (COPD). A systematic review. European Clinical Respiratory Journal, 2017, 4, 1332931.	1.5	19
52	Clinical characteristics and outcome in patients with antisynthetase syndrome associated interstitial lung disease: a retrospective cohort study. European Clinical Respiratory Journal, 2019, 6, 1583516.	1.5	19
53	Effect of a New Tele-Rehabilitation Program versus Standard Rehabilitation in Patients with Chronic Obstructive Pulmonary Disease. Journal of Clinical Medicine, 2022, 11, 11.	2.4	19
54	Patient-reported outcomes and patient-reported outcome measures in interstitial lung disease: where to go from here?. European Respiratory Review, 2021, 30, 210026.	7.1	17

#	Article	IF	Citations
55	Immunoglobulin G4-related pleuritis â€“ A case report. Respiratory Medicine Case Reports, 2016, 19, 18-20.	0.4	16
56	Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation. Annals of the American Thoracic Society, 2019, 16, 927-930.	3.2	16
57	Childhood pneumothorax in Birtâ€Hoggâ€DubÃ© syndrome: A cohort study and review of the literature. Molecular Genetics & Genomic Medicine, 2018, 6, 332-338.	1.2	15
58	Design of a Study Assessing Disease Behaviour During the Peri-Diagnostic Period in Patients with Interstitial Lung Disease: The STARLINER Study. Advances in Therapy, 2019, 36, 232-243.	2.9	15
59	Augmented reality glasses as a new tele-rehabilitation tool for home use: patientsâ€™ perception and expectations. Disability and Rehabilitation: Assistive Technology, 2022, 17, 480-486.	2.2	15
60	Patient reported outcome measures (PROMs) in sarcoidosis. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2017, 34, 2-17.	0.2	15
61	Eight novel variants in the SLC34A2 gene in pulmonary alveolar microlithiasis. European Respiratory Journal, 2020, 55, 1900806.	6.7	14
62	Interstitial Lung Disease in Connective Tissue Diseases: Survival Patterns in a Population-Based Cohort. Journal of Clinical Medicine, 2021, 10, 4830.	2.4	14
63	Cultural Differences in Palliative Care in Patients With Idiopathic Pulmonary Fibrosis. Chest, 2015, 148, e56.	0.8	13
64	NT-proBNP <95 ng/l can exclude pulmonary hypertension on echocardiography at diagnostic workup in patients with interstitial lung disease. European Clinical Respiratory Journal, 2016, 3, 32027.	1.5	13
65	Continous Rituximab treatment for recurrent diffuse alveolar hemorrhage in a patient with systemic lupus erythematosus and antiphosholipid syndrome. Respiratory Medicine Case Reports, 2017, 22, 263-265.	0.4	13
66	Coâ€morbidity and mortality among patients with interstitial lung diseases: A populationâ€based study. Respirology, 2018, 23, 606-612.	2.3	13
67	Danish respiratory society position paper: palliative care in patients with chronic progressive non-malignant lung diseases. European Clinical Respiratory Journal, 2018, 5, 1530029.	1.5	13
68	Tele-delivered mindfulness-based cognitive therapy in chronic obstructive pulmonary disease: A mixed-methods feasibility study. Journal of Telemedicine and Telecare, 2019, 25, 468-475.	2.7	13
69	Outcomes of patients with advanced idiopathic pulmonary fibrosis treated with nintedanib or pirfenidone in a realâ€world multicentre cohort. Respirology, 2021, 26, 982-988.	2.3	13
70	Clusters of comorbidities in idiopathic pulmonary fibrosis. Respiratory Medicine, 2021, 185, 106490.	2.9	13
71	PD-L1 Expression in Patients with Idiopathic Pulmonary Fibrosis. Journal of Clinical Medicine, 2021, 10, 5562.	2.4	13
72	Lung ultrasound has limited diagnostic value in rare cystic lung diseases: a cross-sectional study. European Clinical Respiratory Journal, 2017, 4, 1330111.	1.5	12

#	Article	IF	Citations
73	COPD: an overlooked cause of excess mortality in patients with rheumatoid arthritis. Lancet Respiratory Medicine,the, 2018, 6, 326-327.	10.7	12
74	Advance care planning for patients with lung, heart and cancer diseases and their relatives. International Journal of Palliative Nursing, 2019, 25, 112-127.	0.5	12
75	Attitude and Barriers in Palliative Care and Advance Care Planning in Nonmalignant Chronic Lung Disease: Results From a Danish National Survey. Journal of Palliative Care, 2020, 35, 232-235.	1.0	12
76	Integration of cryobiopsies for interstitial lung disease diagnosis is a valid and safe diagnostic strategyâ€"experiences based on 250 biopsy procedures. Journal of Thoracic Disease, 2021, 13, 1455-1465.	1.4	12
77	Pulmonary alveolar microlithiasis: no longer in the stone age. ERJ Open Research, 2020, 6, 00289-2020.	2.6	12
78	Review of IPF diagnosis and management recommendations in Europe. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2013, 30, 249-61.	0.2	12
79	Fatigue Is a Major Symptom at COVID-19 Hospitalization Follow-Up. Journal of Clinical Medicine, 2022, 11, 2411.	2.4	12
80	Cryobiopsies are diagnostic in Pleuroparenchymal and Airway-centered Fibroelastosis. Respiratory Research, 2018, 19, 135.	3.6	11
81	Report Standardization in Transbronchial Lung Cryobiopsy. Archives of Pathology and Laboratory Medicine, 2019, 143, 416-417.	2.5	10
82	Identifying unmet needs in SSc-ILD by semi-qualitative in-depth interviews. Rheumatology, 2021, 60, 5601-5609.	1.9	10
83	The case of methotrexate and the lung: Dr Jekyll and Mr Hyde. European Respiratory Journal, 2021, 57, 2100079.	6.7	10
84	Lung Ultrasound to Phenotype Chronic Lung Allograft Dysfunction in Lung Transplant Recipients. A Prospective Observational Study. Journal of Clinical Medicine, 2021, 10, 1078.	2.4	10
85	Organisation of diagnosis and treatment of idiopathic pulmonary fibrosis and other interstitial lung diseases in the Nordic countries. European Clinical Respiratory Journal, 2015, 2, 28348.	1.5	9
86	Hypersensitivity pneumonitis among wind musicians â€“ an overlooked disease?. European Clinical Respiratory Journal, 2017, 4, 1351268.	1.5	9
87	Granulomatous-lymphocytic interstitial lung disease and recurrent sinopulmonary infections in a patient with Goodâ€™s syndrome. BMJ Case Reports, 2015, 2015, bcr2014205635.	0.5	9
88	Advance care planning and longer survival in the terminally ill: a randomised controlled trial unexpected finding. BMJ Supportive and Palliative Care, 2020, 10, 221-222.	1.6	8
89	Screening Tools for Depression and Anxiety in Patients with Chronic Obstructive Pulmonary Disease â€“ A Systematic Review. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2021, 18, 683-689.	1.6	8
90	Management of Acute Exacerbation of Idiopathic Pulmonary Fibrosis in Specialised and Non-specialised ILD Centres Around the World. Frontiers in Medicine, 2021, 8, 699644.	2.6	8

#	Article	IF	Citations
91	A pilot study on the use of the super dimension navigation system for optimal cryobiopsy location in interstitial lung disease diagnostics. Pulmonology, 2023, 29, 119-123.	2.1	8
92	Changes in management of idiopathic pulmonary fibrosis: impact on disease severity and mortality. European Clinical Respiratory Journal, 2020, 7, 1807682.	1.5	7
93	High turnover of types <scp>III</scp> and <scp>VI</scp> collagen in progressive idiopathic pulmonary fibrosis. Respirology, 2021, 26, 582-589.	2.3	7
94	An RCT of acute health effects in COPD-patients after passive vape exposure from e-cigarettes. European Clinical Respiratory Journal, 2021, 8, 1861580.	1.5	7
95	Eosinophil alveolitis in two patients with idiopathic pulmonary fibrosis. Respiratory Medicine Case Reports, 2016, 19, 61-64.	0.4	6
96	Fatigue in idiopathic pulmonary fibrosis measured by the Fatigue Assessment Scale during antifibrotic treatment. European Clinical Respiratory Journal, 2021, 8, 1853658.	1.5	6
97	Disease Behaviour During the Peri-Diagnostic Period in Patients with Suspected Interstitial Lung Disease: The STARLINER Study. Advances in Therapy, 2021, 38, 4040-4056.	2.9	6
98	Lung Ultrasound â€“ A Novel Diagnostic Tool To Phenotype Chronic Lung Allograft Dysfunction?. Ultrasound International Open, 2017, 03, E117-E119.	0.6	5
99	Remarkable benefits of intravenous immunoglobulin (IVIG) in a patient with polymyositis-associated acute interstitial lung disease. European Clinical Respiratory Journal, 2020, 7, 1840706.	1.5	5
100	A global perspective on acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF): results from an international survey. , 2018, , .		5
101	Longitudinal serological assessment of type VI collagen turnover is related to progression in a real-world cohort of idiopathic pulmonary fibrosis. BMC Pulmonary Medicine, 2021, 21, 382.	2.0	5
102	Comorbidities in unclassifiable interstitial lung disease. Respiratory Research, 2022, 23, 59.	3.6	5
103	Increasing awareness of corticosteroid hypersensitivity reactions is important. Respirology Case Reports, 2013, 1, 43-45.	0.6	4
104	Tracheal collapse diagnosed by multidetector computed tomography: evaluation of different image analysis methods. European Clinical Respiratory Journal, 2017, 4, 1407624.	1.5	4
105	Autoimmune pulmonary alveolar proteinosis in an adolescent successfully treated with inhaled rhGM-CSF (molgramostim). Respiratory Medicine Case Reports, 2018, 23, 167-169.	0.4	4
106	Economic consequences of idiopathic pulmonary fibrosis in Denmark. ERJ Open Research, 2018, 4, 00045-2017.	2.6	4
107	Familial idiopathic pulmonary fibrosis in a young female. Respiratory Medicine Case Reports, 2018, 24, 1-4.	0.4	4
108	Surgical Lung Biopsy and Cryobiopsy in Fibrosing Interstitial Lung Diseases: One Swallow Does Not Make a Summer. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 939-940.	5.6	4

#	Article	IF	Citations
109	Tracheal collapsibility in adults is dynamic over time. Respiratory Medicine, 2019, 146, 124-128.	2.9	4
110	Interstitial lung diseases: quo vadis?. Lancet Respiratory Medicine,the, 2021, 9, 1084-1087.	10.7	4
111	Emphysema mimicking interstitial lung disease: Two case reports. Respiratory Medicine Case Reports, 2015, 15, 24-26.	0.4	3
112	The effect of the walk-bike on quality of life and exercise capacity in patients with idiopathic pulmonary fibrosis: a feasibility study. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2020, 37, 192-202.	0.2	3
113	Impaired phosphate transport in SLC34A2 variants in patients with pulmonary alveolar microlithiasis. Human Genomics, 2022, 16, 13.	2.9	3
114	No effect of pirfenidone treatment in fulminant bleomycin-induced pneumonitis. Respiratory Medicine Case Reports, 2014, 12, 47-49.	0.4	2
115	Pulmonary hemorrhage following anabolic agent abuse: Two cases. Respiratory Medicine Case Reports, 2016, 18, 45-47.	0.4	2
116	Early referral to palliative care in IPF â€“ pitfalls and opportunities in clinical trials. Respiratory Research, 2020, 21, 174.	3.6	2
117	Comparison of Palliative Care Models in Idiopathic Pulmonary Fibrosis. Applied Sciences (Switzerland), 2021, 11, 9028.	2.5	2
118	Suggestions for improving clinical utility of future guidelines for diagnosis and management of idiopathic pulmonary fibrosis: results of a Delphi survey. European Respiratory Journal, 2021, 57, 2004219.	6.7	2
119	Validation of a derived version of the IPF-specific Saint Georgeâ€™s Respiratory Questionnaire. Respiratory Research, 2021, 22, 259.	3.6	2
120	Erectile dysfunction is a common problem in interstitial lung diseases. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2017, 34, 356-364.	0.2	2
121	Challenges in the classification of fibrotic ILD. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2015, 32 Suppl 1, 4-9.	0.2	2
122	Careful Planning Reduces Cryobiopsy Complications. Annals of the American Thoracic Society, 2017, 14, 1229.	3.2	2
123	Acute Exacerbations in Patients with Progressive Fibrosing Interstitial Lung Diseases: Data from the INBUILD Trial. , 2022, , .		2
124	Real-World Data on Bleeding Risk and Anticoagulation in Patients with IPF Treated with Antifibrotics. Drug Safety, 2020, 43, 953-955.	3.2	1
125	International multidisciplinary team discussions on the diagnosis of idiopathic non-specific interstitial pneumonia and the development of connective tissue disease. European Clinical Respiratory Journal, 2021, 8, 1933878.	1.5	1
126	Decline in Forced Vital Capacity as a Surrogate for Mortality in Patients with Fibrosing Interstitial Lung Diseases. , 2021, , .		1

#	Article	IF	Citations
127	Efficacy and safety of nintedanib in the elderly patient with IPF. , 2019, , .		1
128	New-onset asthma in a bilateral lung transplant patient. BMJ Case Reports, 2019, 12, e231654.	0.5	1
129	Pulmonary Alveolar Microlithiasis - A Review.. Yale Journal of Biology and Medicine, 2021, 94, 637-644.	0.2	1
130	Intravenous immunoglobulin treatment stabilizing a patient with Anti-PL7 antisynthetase syndrome with interstitial lung disease and eosinophilic inflammation. Respiratory Medicine Case Reports, 2022, , 101686.	0.4	1
131	0191â€…Are indoor concentrations of airborne mould spores in non-industrial environments sufficiently high to cause hypersensitivity pneumonitis?. Occupational and Environmental Medicine, 2014, 71, A85.2-A85.	2.8	0
132	O40-1â€…Risk of hypersensitivity pneumonitis and other interstitial lung diseases among pigeon breeders. , 2016, , .		0
133	FRI0174â€…A population based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality. , 2017, , .		0
134	0435â€…Pigeon breeding and the risk of interstitial lung disease, does number of pigeons matter?. , 2017, , .		0
135	Differences in the Approach to Acute Exacerbation of Idiopathic Pulmonary Fibrosis (AE IPF) Between Expert Centres and General Pulmonologists: Results from an International Survey. , 2019, , .		0
136	Pulmonary alveolar proteinosis - a crazy presentation of dyspnea. European Clinical Respiratory Journal, 2019, 6, 1552065.	1.5	0
137	Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Multiple Comorbidities. , 2020, , .		0
138	Inhaled GM-CSF (Molgramostim) Therapy Reduces the Need for Whole Lung Lavage in Patients with Autoimmune Pulmonary Alveolar Proteinosis - Long-Term Results from a Randomized, Double-Blind Trial (IMPALA). , 2020, , .		0
139	A Pilot Study on the Utility of SuperDimension to Guide Cryobiopsies in ILDs. , 2021, , .		0
140	Fibrin Formation Measured in Serum Is Related to Disease Severity in IPF Patients. , 2021, , .		0
141	Estimated Global Prevalence of Idiopathic Pulmonary Fibrosis. , 2021, , .		0
142	Health Related Quality of Life and Symptoms Are Related to Mortality in Idiopathic Pulmonary Fibrosis. , 2021, , .		0
143	Ein globaler Blick auf akute Exazerbationen der idiopathischen Lungenfibrose (AE-IPF): Ergebnisse einer internationalen Umfrage. , 2019, 73, .		0
144	P-101â€…Occupational dust exposures and CT findings of interstitial lung disease and chronic obstructive pulmonary disease. , 2021, , .		0

#	Article	IF	Citations
145	Efficacy and safety of nintedanib in the elderly patient with IPF*. , 2020, 74, .		0
146	Design and rationale of ProSar, the first Danish sarcoidosis registry.. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2022, 38, e2021044.	0.2	0
147	Characteristics of Danish Patients with Pulmonary Sarcoidosis. , 2022, , .		0
148	Efficacy and Safety of Nintedanib in Elderly Patients with Progressive Fibrosing Interstitial Lung Diseases (ILDs). , 2022, , .		0
149	A Neo-Epitope Biomarker ofType VI Collagen Formation Reflects Patient-Reported Outcomes. , 2022, , .		0
150	Lung Cancer in Patients with Idiopathic Pulmonary Fibrosis: A Retrospective Multicenter Study in Europe. , 2022, , .		0
151	Effect of a Telerehabilitation program in sarcoidosis.. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2022, 39, e2022003.	0.2	0
152	Decline in forced vital capacity as a surrogate for mortality in patients with fibrosing interstitial lung diseases*. Pneumologie, 2022, , .	0.1	0